CLINICAL TRIALS PROFILE FOR BUPIVACAINE HYDROCHLORIDE; EPINEPHRINE
✉ Email this page to a colleague
All Clinical Trials for bupivacaine hydrochloride; epinephrine
| Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|
| NCT00298571 ↗ | Cesarean Delivery and Post-operative Pain Management With Local Anesthesia | Completed | University of South Florida | Phase 2/Phase 3 | 2006-02-01 | The use of .5% Bupivacaine with epinephrine at the time of skin closure in cesarean deliveries will decrease post-op pain. |
| NCT00458003 ↗ | Phenylephrine in Spinal Anesthesia in Preeclamptic Patients | Completed | Northwestern University | N/A | 2006-07-01 | Hypotension remains a common clinical problem after induction of spinal anesthesia for cesarean delivery. Maternal hypotension has been associated with considerable morbidity (maternal nausea and vomiting and fetal/neonatal acidemia). Traditionally, ephedrine has been the vasopressor of choice because of concerns about phenylephrine's potential adverse effect on uterine blood flow. This practice was based on animal studies which showed that ephedrine maintained cardiac output and uterine blood flow, while direct acting vasoconstrictors, e.g., phenylephrine, decreased uteroplacental perfusion. However, several recent studies have demonstrated that phenylephrine has similar efficacy to ephedrine for preventing and treating hypotension and may be associated with a lower incidence of fetal acidosis. All of these studies have been performed in healthy patients undergoing elective cesarean delivery. Preeclampsia complicates 5-6% of all pregnancies and is a significant contributor to maternal and fetal morbidity and mortality. Many preeclamptic patients require cesarean delivery of the infant. These patients often have uteroplacental insufficiency. Given the potential for significant hypotension after spinal anesthesia and its effect on an already compromised fetus, prevention of (relative) hypotension in preeclamptic patients is important. Spinal anesthesia in preeclamptic patients has been shown to have no adverse neonatal outcomes as compared to epidural anesthesia when hypotension is treated adequately. Due to problems related to management of the difficult airway and coagulopathy, both of which are more common in preeclamptic women, spinal anesthesia may be the preferred regional anesthesia technique. Recent studies have demonstrated that preeclamptic patients may experience less hypotension after spinal anesthesia than their healthy counterparts. To our knowledge, phenylephrine for the treatment of spinal anesthesia-induced hypotension has not been studied in women with preeclampsia. The aim of our study is to compare intravenous infusion regimens of phenylephrine versus ephedrine for the treatment of spinal anesthesia induced hypotension in preeclamptic patients undergoing cesarean delivery. The primary outcome variable is umbilical artery pH. |
| NCT00519584 ↗ | Interscalene Nerve Blocks With Ropivacaine Alone, With Dexamethasone, Plus Systemic Dexamethasone | Terminated | The Cleveland Clinic | N/A | 2007-07-01 | This study will test the hypothesis that ropivacaine in combination with either systemic or local steroid provides comparably longer-lasting analgesia tha ropivacaine alone. |
| NCT00531349 ↗ | Regional Anesthesia and Endometrial Cancer Recurrence | Withdrawn | The Cleveland Clinic | Phase 3 | 2007-11-01 | The purpose of this study is to determine whether recurrence of local and metastatic cancer after open hysterectomy for stage 1 or 2 endometrial cancer is reduced when patients receive epidural anesthesia/analgesia combined with propofol sedation rather than sevoflurane anesthesia and opioid analgesia. |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for bupivacaine hydrochloride; epinephrine
Condition Name
Clinical Trial Locations for bupivacaine hydrochloride; epinephrine
Trials by Country
Clinical Trial Progress for bupivacaine hydrochloride; epinephrine
Clinical Trial Phase
Clinical Trial Sponsors for bupivacaine hydrochloride; epinephrine
Sponsor Name
